The Sciety syndicate invests MSEK 15 in cutting-edge company specializing in DNA sequencing

2019-06-12

This week, Single Technologies completed a new share issue of 15 million SEK with Sciety. The company has developed a DNA sequencing solution, which makes it possible to analyse larger amounts of data faster and cheaper than before. The new capital will be used to adapt the instrument for NGS…

Read more

Athera Biotechnologies raises MSEK 55 with the help of Sciety

2019-05-14

This week, pharmaceutical company Athera Biotechnologies, completed a new share issue of SEK 55 million in which Industrifonden, Östersjöstiftelsen and the Sciety investment syndicate participated. The new capital is to be used for a clinical Phase 2 study and the company aims at being acquired by a major player after…

Read more

Sciety raises new capital for a medtech company to continue their expansion in Europe

2019-04-02

Medtech company Likvor raises new capital for its continued expansion in Europe. They currently have about ten hospitals as clients. The company’s system is used to diagnose the dementia-like disorder, NPH. Likvor has developed a system for the monitoring of cerebrospinal spinal fluid dynamics to investigate and follow up the…

Read more

Sciety raises new capital for pharma company within fat-related diseases

2019-03-26

Lipigon Pharmaceuticals has raised SEK 8 million in a new share issue to finance the continued pre-clinical development of pharmaceuticals within fat-related diseases, so-called lipid-related disorders. Lipid imbalance cause common diseases, such as diabetes and cardiovascular diseases, but also a number of rare diseases currently lacking sufficient treatment. Based on…

Read more

Sciety arranges two private placements

2019-02-11

Sciety is currently capitalizing a Phase II pharmaceutical company and a DNA sequencing tech company––both via private placements. The companies operate in high growth markets and raise new capital to achieve product development goals that will lead to acquisition within the next twenty-four months.     Drug candidate with a…

Read more

New venture at Sciety – develops drugs for diseases caused by high levels of blood lipids

2018-11-26

Lipid imbalances does not only cause common diseases such as diabetes and cardiovascular diseases but also various rare diseases. The pharma company Lipigon is specialised in diseases caused by lipid imbalances, with an initial focus on rare diseases that lack adequate treatments.   New candidate for treatment of severe disease…

Read more

Sciety raises new capital to medtech company in neurology and cancer

2018-10-09

CARTANA raised almost 10 million SEK in a share issue that was fully subscribed at the end of September. The company has developed reagents for analysing tissue samples in drug development processes and is based at Karolinska in Stockholm. The new capital will be used for the sale of CARTANA’s…

Read more

New venture at Sciety – wants to help researchers in the search for new treatments

2018-09-19

Cartana is based at Karolinska Institute in Stockholm and has developed a new technology for researchers to analyse tissue samples in drug development processes. The company is ready to launch at the market for brain research and will launch on the market for cancer research within a few years.  …

Read more

Opportunity to join Cartana – their technology revolutionizes the brain research

2018-08-22

Neurological disorders have been pinpointed by WHO as one of the greatest threats to public health. As an example, nearly 10 million people develop dementia each year and the number of people living with dementia is expected to triple from 50 million to 152 million by 2050. Today, the annual…

Read more

Sciety becomes a member in SwedenBIO

2018-06-18

Sciety becomes a member in the trade association SwedenBIO that works for a strong life science sector in Sweden. The members include micro companies to big pharma but also companies that provide services in business development, IP, financing and etc. As Sciety works with financing of unlisted companies, in the…

Read more